On the part of the gastrointestinal tract: often – nausea, diarrhea, constipation. On the part of the kidney and urinary tract: the frequency is unknown – polyuria, urinary incontinence. From the genital and breast cancer: an unknown frequency of sexual dysfunction, priapism. immune system: rarely – hypersensitivity; the frequency is unknown – anaphylactic reactions (including anaphylactic shock), allergic reactions (rash, maculopapular rash). From the nervous system: very often – drowsiness; often – asthenia, extrapyramidal disorders (especially in children and young patients and / or in excess of the recommended doses of the drug, even after a single administration), parkinsonism, akathisia: Infrequent proviron steroid – dystopia, dyskinesia. impaired consciousness: rarely – seizures, particularly in patients with epilepsy; the frequency is unknown – tardive dyskinesia. sometimes persistent, during, or after prolonged treatment, especially in elderly patients, neuroleptic malignant syndrome. Mental Disorders: often – depression; rarely – hallucinations; rarely confusion. Adverse reactions, common with high doses of the drug – Extrapyramidal symptoms: acute dystonia and dyskinesia, akathisia syndrome parkinsonizmab develop even after the use of a single dose of the drug, especially in children and young adults (sm. section “Special Instructions”) . – Drowsiness, decreased level of consciousness, confusion, hallucinations.
Extrapyramidal disorders, drowsiness, decreased level of consciousness, confusion, hallucinations, irritability, dizziness, bradycardia, changes in blood pressure, heart failure and breathing, pain in the abdomen. Treatment In case of extrapyramidal symptoms caused by overdose or some other reason, treatment is exclusively symptomatic (benzodiazepines in children and / or anticholinergic antiparkinsonian drugs in adults). It requires symptomatic treatment and constant monitoring of cardiac and respiratory functions, depending on the patient’s clinical condition. There is no specific proviron steroid antidote.
Interaction with other drugs
Concomitant use of metoclopramide with levodopa or dopamine receptor agonists in connection with the existing mutual antagonism.
Alcohol increases the sedative effect of metoclopramide. Combinations requiring compliance with caution in connection with the prokinetic effect of metoclopramide, the absorption of certain drugs may be affected. M-holinoblokatory and morphine derivatives have mutual antagonism with metoclopramide regarding effect on the motility of the gastrointestinal tract. drugs, proviron steroid depressants (morphine derivatives, tranquilizers blockers H1-histamine receptor antidepressants sedating barbiturates, clonidine and other formulations of these groups) may increase sedation influenced metoclopramide. metoclopramide increases the effects of antipsychotics in relation to extrapyramidal symptoms. if concomitant use of the inside of metoclopramide and tetrabenazine is probable that the deficit of dopamine, which may be accompanied by increased muscle stiffness or spasm, difficulty in speaking or swallowing, anxiety, tremor, involuntary muscle movements, including facial muscles. The use of metoclopramide with serotonergic drugs such as selective serotonin reuptake inhibitors, increases the risk of serotonin syndrome (serotonin intoxication). metoclopramide reduces the bioavailability of digoxin. It is to monitor the concentration of digoxin in plasma. Metoclopramide improves the bioavailability of cyclosporin. It is necessary to carefully monitor the concentration of cyclosporine in the blood plasma. The clinical consequences of such interactions have not been established. Exposure metoclopramide increases while the use of potent inhibitors of isoenzyme CYP2D6. such as fluoxetine and paroxetine. Although the clinical significance of proviron steroid this interaction has not been established, you must let me know when patients adverse reactions